33 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
may set;
If we are unable to comply, or have not fully complied, with applicable federal and state healthcare fraud and abuse laws, false claims laws … , health information privacy and security laws, and other healthcare laws and regulations, we could face substantial penalties;
If we are unable
6-K
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results … healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended
6-K
EX-99.2
OBSVF
ObsEva SA
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
of the European Commission and the UK Medicines and Healthcare Products Regulatory Agency in June 2022. As a result of the termination of the Kissei License
6-K
EX-99.1
OBSVF
ObsEva SA
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
and Healthcare Products Regulatory Agency in June 2022.
ObsEva intends to restructure its operations to support existing license agreements, namely its
6-K
EX-99.1
OBSVF
ObsEva SA
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
and commercializing novel therapies for women’s health, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted … to and understand its patients, serve their needs and offer healthcare solutions to help improve their lives. Theramex’s vision is to be a lifetime partner for women
6-K
EX-99.1
x1u8l0wpd6vls1ef160
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
qfvoja84
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
8cq5gn17zj
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
EX-99.1
5mnzgr 25n5
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
8n4uizbadv qopp3
27 Jul 21
Current report (foreign)
6:12am
6-K
EX-99.1
yrweerwouq0mj8 hdpwu
17 Feb 21
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
6:04am
6-K
EX-99.1
314x0uukiwu cs
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
424B5
5ndjfa6pokgb9qgml8f
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
tjm6mzehj8 6mfu
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
jyq i0lr3
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.3
fgtm0
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
7vr4auh
23 Mar 20
ObsEva Provides Update Related to COVID-19 Pandemic
4:00pm